

IFNγ ELISpot Kit (Murine)

Instructions for use

Catalogue Numbers:

	Pre-coated
1x96 tests	OKDB00035
5x96 tests	OKDB00036

For research use only

Table of Contents

1.	Intended Use	.2
2.	Introduction	.2
2.1.	Summary	.2
2.2.	Principle Of The Method	.3
3.	Reagents Provided (Contents Shown For 5x96 Test Format)	.4
4.	Materials/Reagents Required But Not Provided	.4
5.	Storage Instructions	.4
6.	Safety & Precautions For Use	.5
7.	Reagent Preparation	.6
7.1.	1x Phosphate Buffered Saline (PBS)	.6
7.2.	1% BSA PBS Solution (Dilution Buffer)	.6
7.3.	0.05% PBS-T Solution (Wash Buffer)	.6
7.4.	Detection Antibody	. 6
7.5.	Streptavidin – AP Conjugate	. 6
7.6.	BCIP / NBT	.6
8.	Sample And Control Preparation	.7
8.1.	Cell Stimulation	.7
8.2.	Positive Assay Control, IFNγ Production	.7
8.3.	Negative Assay Control	.7
8.4.	Sample	.7
9.	Method	. 8
10.	Performance Characteristics	. 9
10.1	Reproducibility And Linearity	. 9
11.	Bibliography	10
12.	Aviva Murine IFNγ ELISpot References	11

Murine IFNγ ELISpot KIT – Pre-coated

1. Intended use

Aviva **ELISpot** is a highly specific immunoassay for the analysis of cytokine and other soluble molecule production and secretion from T-cells at a single cell level in conditions closely comparable to the *in-vivo* environment with minimal cell manipulation. This technique is designed to determine the frequency of cytokine producing cells under a given stimulation and the comparison of such frequency against a specific treatment or pathological state. The ELISpot assay constitutes an ideal tool in the investigation of Th1 / Th2 responses, vaccine development, viral infection monitoring and treatment, cancerology, infectious disease, autoimmune diseases and tranplantation.

Utilising sandwich immuno-enzyme technology, Aviva ELISpot assays can detect both secreted cytokines and single cells that simultaneously produce multiple cytokines. Cell secreted cytokines or soluble molecules are captured by coated antibodies avoiding diffusion in supernatant, protease degradation or binding on soluble membrane receptors. After cell removal, the captured cytokines are revealed by tracer antibodies and appropriate conjugates.

This kit has been configured for research use only and is not to be used in diagnostic procedures.

2. Introduction

2.1. Summary

Different populations of T-cells secrete differing patterns of cytokines that ultimately lead to different immune responses. IFN- γ production is a key function of Th1, CD8⁺ CTLs and also NK cells. IFN- γ is a cytokine critical for cell mediated immunity against viral and intracellular bacterial infections and is involved in the inflammatory response following secretion via macrophage activation and stimulation of antibody secretion. IFN- γ is the hallmark effector cytokine of Th1 and therefore is an excellent marker for identifying a host response to intracellular pathogens.


IFN- γ is produced during infection by T cells of the cytotoxic/suppressor phenotype (CD8) and by a subtype of helper T cells, the Th1 cells. Th1 cells secrete IL-2, IL-3, TNF α and IFN- γ , whereas Th2 cells mainly produce IL-3, IL-4, IL-5, and IL-10, but little or no IFN- γ (1). IFN- γ preferentially inhibits the proliferation of Th2 but not Th1 cells, indicating that the presence of IFN- γ during an immune response will result in the preferential proliferation of Th1 cells (2).

In addition, IFN- γ has several properties related to immunoregulation. IFN- γ is a potent activator of mononuclear phagocytes(*3*), and activates macrophages to kill tumor cells by releasing reactive oxygen intermediates and TNF α (*4*). IFN- γ induces or augments the expression of MHC antigens on macrophages, T and B cells and some tumor cell lines (*5*). On T and B cells IFN- γ promotes differentiation. It enhances proliferation of activated B cells and can act synergistically with IL-2 to increase immunoglobulin light-chain synthesis (*6*, *7*).

The role of IFN- γ as a disease marker has been demonstrated for a number of different pathological situations including, viral infection (8), Autoimmune disease (9), transplant rejection (10), Diabetes (5) and allergy (11).

2.2. Principle of the method

Capture antibodies highly specific for the analyte of interest are coated to the wells of a PVDF bottomed 96 well microtitre plate either during kit manufacture or in the laboratory. The plate is then blocked to minimise any non-antibody dependent unspecific binding and finally washed before adding the cells to be investigated. Cell suspension and stimulant are added to the coated and blocked microtitre plate and the plate incubated allowing the specific antibodies to bind any analytes produced. Biotinylated detection antibodies are then added which bind to the previously captured analyte. Enzyme conjugated Streptavidin is added binding to the detection antibodies. Any excess unbound analyte and antibodies are removed by careful washing. Colour substrate is then applied to the wells resulting in coloured spots which can be quantified using appropriate analysis software or manually using microscopes.



3. Reagents provided (Contents shown for 5x96 test format)

- Pre-coated 96 well PVDF bottomed plates (5)
- Biotinylated detection antibody (lyophilised, resuspend in 0.55ml)
- Streptavidin-Alkaline Phosphatase conjugate (50µl)
- Bovine Serum Albumin (BSA)
- Ready to use BCIP/NBT substrate buffer (50ml)

Please note for 1x96 demo kits, Biotinylated detection antibody is provided in liquid form.

4. Materials/Reagents required but not provided

- · Miscellaneous laboratory plastic and/or glass, if possible sterile
- Cell culture reagents (e.g. RPMI-1640, L-glutamine, FCS)
- Cell stimulation reagents (e.g. PMA, Ionomycin, mIL-2, Concanavalin A)
- CO₂ incubator
- Tween 20
- Phosphate Buffered Saline (PBS)

5. Storage Instructions

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2 to 8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if in the case of repeated use of one component, the reagent is not contaminated by the first handling.

6. Safety & Precautions for use

- For research use only not to be used as a diagnostic test
- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g.CDC/NIH Health manual : " Biosafety in Microbiological and Biomedical Laboratories" 1984
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use.
- Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- **BCIP/NBT buffer** is potentially carcinogenic and should be disposed of appropriately, caution should be taken when handling this reagent, always wear gloves
- Follow incubation times described in the assay procedure

7. Reagent Preparation

7.1. 1X Phosphate Buffered Saline (PBS)

For 1 litre of 10X PBS weigh-out: 80g NaCl 2g KH₂PO₄ 14.4g Na₂HPO₄ ₂H₂O.

Add distilled water to 1 litre. Adjust the pH of the solution to 7.4 +/- 0.1 were required.

Dilute the solution to 1X before use.

7.2. 1% BSA PBS Solution (Dilution Buffer)

For one plate dissolve 0.2 g of BSA in 20 ml of 1X PBS.

7.3. 0.05% PBS-T Solution (Wash Buffer)

For one plate dissolve 50µl of Tween 20 in 100 ml of 1X PBS.

7.4. Detection Antibody

Reconstitute the lyophilised antibody with 0.55mL of distilled water. Gently mix the solution and wait until all the lyophilised material is back into solution.

Please note for 1x96 demo kits, Biotinylated detection antibody is provided in liquid form.

If not used within a short period of time, reconstituted Detection Antibody should be aliquoted and stored at -20°C. In these conditions the reagent is stable for at least one year. For optimal performance prepare the reconstituted antibody dilution immediately prior to use.

Dilute 100μ l of antibody into 10ml Dilution Buffer and mix well. For optimal performance, filter the solution using a disposable syringe and a 0.2µm filter disc.

7.5. Streptavidin – AP conjugate

For optimal performance prepare the Streptavidin-AP dilution immediately prior to use

For 1 plate dilute 10µl of Streptavidin-AP conjugate into 10 mL Dilution Buffer and mix well.

Do not keep this solution for further experiments. For optimal performance, filter the Streptavidin solution using a disposable syringe and a 0.2µm filter disc.

7.6. BCIP/NBT

This reagent is ready-to-use.

In case of precipitation, filter the solution using a disposable syringe and a 0.2µm filter disc to avoid the presence of artifactual spots.

8. Sample and Control Preparation

8.1. Cell Stimulation

Cells can either be stimulated directly in the antibody coated wells (Direct) or, first stimulated in 24 well plates or flask, harvested, and then plated into the coated wells (Indirect).

The method used is dependent on 1) the type of cell assayed 2) the expected cell frequency. When a low number of cytokine producing cells are expected it is also advised to test them with the direct method, however, when this number is particularly high it is better to use the indirect ELISpot method.

All the method steps following stimulation of the cells are the same whatever the method (direct/indirect) chosen.

8.2. Positive Assay Control, IFNγ production

We recommend using the following polyclonal activation as a positive control in your assay.

Dilute mouse splenocytes in culture media (e.g. RPMI 1640 supplemented with 2mM L-glutamine and 10% heat inactivated fetal calf serum) containing containing 0.5μ g/ml Concanavalin A and 2ng/ml mIL-2. Incubate 2 days (Indirect stimulation). Take off non adherent materials and harvest adherent cells with a cell scraper. Wash cells once. Dilute cells in culture media supplemented with 1ng/ml PMA and 500ng/ml ionomycin (Sigma, Saint Louis, MO). Distribute 1×10^5 to 2.5×10^5 cells per 100μ l in required wells of an antibody coated 96-well PVDF plates and incubate for 10-15 hours in an incubator.

For antigen specific stimulation, the optimal concentration of the antigen and the optimal concentration of number of cells have to be determined experimentally, as it is depending on the frequency of cytokine producing cells

8.3. Negative Assay Control

Dilute mouse splenocytes in culture media to give an appropriate cell number (same number of unstimulated cells as stimulated sample cells) per 100μ l with no stimulation.

8.4. Sample

Dilute mouse splenocytes in culture medium and stimulator of interest (i.e. Sample, Vaccine, Peptide pool or infected cells) to give an appropriate cell number per 100µl.

Optimal assay performances are observed between 1×10^5 and 2.5×10^5 cells per 100μ l.

Stimulators and incubation times can be varied depending on the frequency of cytokine producing cells and therefore should be optimised by the testing laboratory.

9. Method

Prepare all reagents as shown in section 7 and 8. Note: For optimal performance prepare the Streptavidin-AP dilution immediately prior to use

Assay Step		Details				
1.	Addition	Add 100µl of 1X PBS to every well				
2.	Incubation	Incubate plate at room temperature (RT) for 10 min				
3.	Wash	Empty the wells by flicking the plate over a sink & gently tapping on absorbent paper.				
4.	Addition	Add 100µl of sample, positive and negative controls cell suspension to appropri wells providing the required concentration of cells and stimulant (cells may have be previously stimulated see section 8.)				
5.	Incubation	Cover the plate and incubate at 37° C in a CO ₂ incubator for an appropriate length of time (10-15 hours) Note: do not agitate or move the plate during this incubation				
6.	Addition	Empty the wells and remove excess solution then add 100μ l of PBS-T to every well				
7.	Incubation	Incubate the plate at 4°C for 10 min				
8.	Wash	Empty the wells as previous and wash the plate $3x$ with 100μ l of PBS-T				
9.	Addition	Add 100µl of diluted detection antibody to every well				
10.	Incubation	Cover the plate and incubate at RT for 1 hour 30 min				
11.	wash	Empty the wells as previous and wash the plate $3x$ with 100μ l of PBS-T				
12.	Addition	Add 100µl of diluted Streptavidin-AP conjugate to every well				
13.	Incubation	Cover the plate and incubate at RT for 1 hour				
14.	Wash	Empty the wells and wash the plate $3x$ with 100μ l of PBS-T				
15.	Wash	Peel of the plate bottom and wash both sides of the membrane 3x under running distilled water, once washing complete remove any excess solution by repeated tapping on absorbent paper.				
16.	Addition	Add 100µl of ready-to-use BCIP/NBT buffer to every well				
17.	Development	Incubate the plate for 5-15 min monitoring spot formation visually throughout the incubation period to assess sufficient colour development				
18.	Wash	Empty the wells and rinse both sides of the membrane 3x under running distilled water. Completely remove any excess solution by gentle repeated tapping on absorbent paper				
Read Spots : allow the wells to dry and then read results. The frequency of the resulting coloured spots corresponding to the cytokine producing cells can be determined using an appropriate ELISpot reader and analysis software or manually using a microscope.						
Note: spots may become sharper after overnight incubation at $4^{\circ}C$						

Plate should be stored at RT away from direct light, but please note colour may fade over prolonged periods so read results within 24 hours.

10. Performance Characteristics

10.1. Reproducibility and Linearity

Intra-assay reproducibility and linearity were evaluated by measuring the spot development following the stimulation (PMA / Ionomycin) of 5 different mouse splenocytes concentrations, 12 repetitions in 1 batch. The data shows the mean spot number, range and CV for the five cell concentrations.

Cells / well	n	Mean number of spots per well	Min	Max	CV%
100000	12	462	406	495	5.5%
50000 recommended	12	494	457	518	3.7%
25000 recommended	12	391	355	411	4.8%
12500	12	244	202	267	7.8%
6250	12	143	120	190	12.5%

11. Bibliography

- 1. 1. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R. L. (1986). Two types of murine helper T cell clone. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357.
- Gajewski, T. F., and Fitch, F. W. (1993). Anti-proliferative effect of IFN-γ in immune regulation. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140, 4245-4252.
- 3. Sastre, L., Roman, J. M., Teplow, D. B., Dreyer, W. J., Gee, C. E., Larson, R. S., Roberts, T. M., and Springer, T. A. (1986). A partial genomic DNA clone for the alpha subunit of the mouse complement receptor type 3 and cellular adhesion molecule Mac-1.Proc. Natl. Acad. Sci. U. S. A. 83, 5644-5648.
- 4. Urban, J. L., Shepard, H. M., Rothstein, J. L., Sugarman, B. J., and Schreiber, H. (1986). Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl. Acad. Sci. U. S. A. 83, 5233-5237.
- Ciampolillo, A., Guastamacchia, E., Caragiulo, L., Lollino, G., De Robertis, O., Lattanzi, V., and Giorgino, R.(1993). In vitro secretion of interleukin-1 beta and interferon-gamma by peripheral blood lymphomononuclear cells in diabetic patients. Diabetes Res. Clin. Pract. 21, 87-93.
- 6. Le thi Bich Thuy, Queen, C., and Fauci, A. S. (1986). Interferon- gamma induces light chain synthesis in interleukin 2 stimulated human B cells. Eur. J. Immunol. 16, 547-550.
- Romagnani, S., Giudizi, M. G., Biagiotti, R., Almerigogna, F., Mingari, C., Maggi, E., Liang, C. M., and Moretta, L. (1986). B cell growth factor activity of interferon-gamma. Recombinant human interferongamma promotes proliferation of anti-mu-activated human B lymphocytes. J. Immunol. 136, 3513-3516.
- 8. Cunningham, A. L., Nelson, P. A., Fathman, C. G., and Merigan, T. C. (1985). Interferon gamma production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. J. Gen. Virol. 66, 249-258.

9. Olsson, T. Multiple sclerosis, cerebrospinal fluid. (1994). Ann. Neurol. 36 Suppl, 100-102.

10.Nast, C. C., Zuo, X. J., Prehn, J., Danovitch, G. M., Wilkinson, A., and Jordan, S. C. (1994). Gamma interferon gene expression in human renal allograft fine-needle aspirates. Transplantation 57,498-502.

11. Suomalainen, H., Soppi, E., Laine, S., and Isolauri, E. (1993). Immunologic disturbances in cow's milk allergy, Evidence for defective interferon-gamma generation. Pediatr. Allergy Immunol. 4, 203-207.

12. Aviva Murine IFNγ ELISpot References

Adotevi, O. et al., J.Virol., 2010.115(15) :3025-3032 Bonduelle, O.et al., J.Immunol., 2012 ;188 :952-956 Chen, A.et al., J.Virol., 2005;79(9):5568-5576 Gaidot, A. et al., Blood, 2011;117(10):2975-2983 Herrmann, A.et al., Cancer Res., 2010;70(19):7455-7464 Johansen, P.et al., Clin.Vaccine Immunol.,2011;18(6):907-913 Kujawski, M.et al., Cancer Res., 2010;70(23):9599-9610 Li H et al., J.Immunol., 2005;174(1):195-204 Luo, D et al., Infect.Immun.,2006 ;74(5) :2734-41 Pere, H. et al., Blood, 2011 ;118(18) :4853-4862 Qui, J. et al., Clin.Vaccine Immunol.,2011 :CVI.00254-10 Musson, J.A. et al., Infect.Immun., 2010 ;IAI.00195-10 Ramakrishna L. et al., J.Virol., 2004;78(17):9174-9189 Someya K. et al. J. Virol., 2004; 78(18):9842-9853 Tsunoda, I. et al., J Virol., 2005 ;79(23) :14640-6 Yan, L. et al., Infect.Immun.,2008 ;IAI.00245-08 Sandoval, F. et al., Science Translational Medicine, 2013;5:172ra20

13. Technical Resources

Technical Support:

For optimal service please be prepared to supply the lot number of the kit used.

USA

Aviva Systems Biology, Corp. 5754 Pacific Center Blvd, Suite 201 San Diego, CA 92121

Phone: 858-552-6979 Toll Free: 888-880-0001 Fax: 858-552-6975

Technical support: techsupport@avivasysbio.com

China

Beijing AVIVA Systems Biology 6th Floor, B Building, Kaichi Tower #A-2 Jinfu Road. Daxing Industrial Development Zone Beijing, 102600, CHINA

Phone: (86)10-60214720 Fax: (86)10-60214722 E-mail: support@avivasysbio.com.cn

中国地址:北京大兴工业开发区金辅路甲2号凯驰大厦 B座6层 (102600)

电话: 010-60214720/21 传真: 010-60214722

产品售前咨询及销售: sales@avivasysbio.com.cn **售后及技**术支持: support@avivasysbio.com.cn